GCP
NRIX icon

GSA Capital Partners’s Nurix Therapeutics NRIX Stock Holding History

GSA Capital Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,739
Closed -$163K – 2018
2025
Q1 		$163K Buy
+13,739
New +$230K 0.01% 1440
2024
Q4 		– Sell
-10,667
Closed -$240K – 1893
2024
Q3 		$240K Sell
10,667
-15,134
-59% -$343K 0.02% 1337
2024
Q2 		$538K Buy
+25,801
New +$402K 0.04% 913
2024
Q1 		– Sell
-24,091
Closed -$249K – 1857
2023
Q4 		$249K Sell
24,091
-171,329
-88% -$1.17M 0.02% 1207
2023
Q3 		$1.54M Buy
195,420
+177,852
+1,012% +$1.62M 0.13% 195
2023
Q2 		$176K Sell
17,568
-54,931
-76% -$560K 0.02% 1306
2023
Q1 		$644K Buy
72,499
+44,532
+159% +$464K 0.06% 557
2022
Q4 		$307K Buy
+27,967
New +$337K 0.04% 916
2022
Q2 		– Sell
-15,963
Closed -$224K – 1679
2022
Q1 		$224K Buy
+15,963
New +$283K 0.03% 1106

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's NRIX Position: Q2 2025 in Review

GSA Capital Partners sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 13,739 shares — an estimated $163K sold.

GSA Capital Partners first reported a position in NRIX in Q1 2022 and held it in 9 quarters. The position peaked at $1.54M in Q3 2023. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

  • GSA Capital Partners reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 13,739 Nurix Therapeutics shares in Q2 2025, an estimated $163K.
  • GSA Capital Partners first reported a position in Nurix Therapeutics in Q1 2022 and held it in 9 quarters.
  • GSA Capital Partners's Nurix Therapeutics position peaked at $1.54M in Q3 2023.
  • 163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.